Barinthus Biotherapeutics plc (BRNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Barinthus Biotherapeutics plc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Barinthus Biotherapeutics plc total liabilities for a breakdown of total debt and financial obligations.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vikas EcoTech Limited
NSE:VIKASECO
|
-0.032x |
|
Morgan Sindall Group PLC
LSE:MGNS
|
-0.023x |
|
Starteck Finance Limited
NSE:STARTECK
|
0.001x |
|
Carimin Petroleum Bhd
KLSE:5257
|
-0.032x |
|
White Horse Bhd
KLSE:5009
|
0.026x |
|
Hotel Royal Chihpen
TWO:5704
|
0.032x |
|
Cue Biopharma
NASDAQ:CUE
|
-0.681x |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Barinthus Biotherapeutics plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more